Objective: Oral isotretinoin can affect inflammation markers in patients with acne vulgaris. This study aims to examine the impact of isotretinoin treatment on inflammatory markers in patients diagnosed with acne vulgaris. Material and Methods: Fifty-five patients diagnosed with moderate or severe acne vulgaris according to the Global Acne Grading Scale were included in this study. Patients were evaluated at regular intervals (at 0, 2nd, and 3rd months) during the treatment period. Complete blood count [including mean platelet volume (MPV), neutrophil-to-lymphocyte ratio (NLR), plateletcrit, platelet distribution width (PDW), platelet-to-lymphocyte ratio (PLR), red cell distribution width (RDW)], Systemic Immune-Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), Aggregate Index of Systemic Inflammation (AISI), monocyte-high-density lipoprotein (HDL) ratio, monocyte-to-lymphocyte ratio (MLR), MPV/platelet ratio, and serum biochemistry panel were assessed during isotretinoin treatment. Additionally, the Acne Quality of Life Scale was used to assess patients' quality of life. Results: A significant increase in PLR and RDW levels was observed during isotretinoin treatment (p<0.05). However, SII, SIRI, AISI, monocyte/HDL ratio, NLR, PDW, MPV, sedimentation rate, and C-reactive protein levels did not show a significant change during isotretinoin treatment (p>0.05). Furthermore, this study demonstrated that oral isotretinoin treatment reduced the severity of acne and improved patients' quality of life. Conclusion: Isotretinoin may have inflammatory effects shown with PLR and RDW. However, other inflammatory markers did not show a significant change during isotretinoin treatment. Further comprehensive studies are needed to better understand the relationship between isotretinoin treatment and inflammatory markers.
Keywords: Isotretinoin; inflammatory markers; acne vulgaris
Amaç: Oral izotretinoin, akne vulgarisli hastalarda inflamasyon belirteçlerini etkileyebilir. Bu çalışma, izotretinoin tedavisinin akne vulgarisli hastaların inflamatuar belirteçleri üzerindeki etkilerini incelemeyi amaçlamaktadır. Gereç ve Yöntemler: Bu çalışmaya, Global Akne Derecelendirme Ölçeği'ne göre orta veya şiddetli akne vulgarisi tanısı alan 55 hasta dâhil edildi. Hastalar, tedavi başlangıcında ve tedavi süresince düzenli aralıklarla (0, 2 ve 3. aylarda) değerlendirildi. Tam kan sayımı [ortalama trombosit hacmi (mean platelet volume ''MPV''), nötrofil-lenfosit oranı (neutrophil-to-lymphocyte ratio ''NLR''), plateletkrit, trombosit dağılım genişliği (platelet distribution width ''PDW''), trombosit-lenfosit oranı (platelet-to-lymphocyte ratio ''PLR''), kırmızı hücre dağılım genişliği (red cell distribution width ''RDW'')], Sistemik İmmün-İnflamasyon İndeksi (Sİİ), Sistemik İnflamasyon Yanıt İndeksi [Systemic Inflammation Response Index (SIRI)], Toplu Sistemik İnflamasyon İndeksi [Aggregate Index of Systemic Inflammation (AISI)], monosit-yüksek yoğunluklu lipoprotein [high-density lipoprotein (HDL)] oranı, monosit-lenfosit oranı [monocyte-to-lymphocyte ratio (MLR)], MPV/trombosit oranı ve serum biyokimya paneli, izotretinoin tedavisi süresince değerlendirildi. Ayrıca, hastaların yaşam kalitesini değerlendirmek için Akne Yaşam Kalitesi Ölçeği kullanıldı. Bulgular: İzotretinoin tedavisi sırasında PLR ve RDW seviyelerinde anlamlı bir artış tespit edildi (p<0,05). Ancak, Sİİ, SIRI, AISI, monosit/HDL oranı, NLR, PDW, MPV, sedimantasyon hızı ve C-reaktif protein düzeyleri izotretinoin tedavisi sırasında anlamlı bir değişiklik göstermedi (p>0,05). Ayrıca, bu çalışma, oral izotretinoin tedavisinin akne şiddetini azalttığını ve hastaların yaşam kalitesini iyileştirdiğini göstermiştir. Sonuç: İzotretinoin, PLR ve RDW ile gösterilebilen inflamatuar etkilere sahip olabilir. Ancak, izotretinoin tedavisi sırasında diğer inflamatuar belirteçlerde belirgin bir değişiklik gözlenmemiştir. İzotretinoin tedavisi ile inflamasyon belirteçleri arasındaki ilişkiyi daha iyi anlamak için daha fazla kapsamlı çalışmalara ihtiyaç vardır.
Anahtar Kelimeler: İzotretinoin; inflamatuar belirteçler; akne vulgaris
- Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379(9813):361-72. Erratum in: Lancet. 2012;379(9813):314. [Crossref] [PubMed]
- Tanghetti EA. The role of inflammation in the pathology of acne. J Clin Aesthet Dermatol. 2013;6(9):27-35. [PubMed] [PMC]
- Zouboulis CC. Is acne vulgaris a genuine inflammatory disease? Dermatology. 2001;203(4):277-9. [Crossref] [PubMed]
- Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003;121(1):20-7. [Crossref] [PubMed]
- Kang S, Cho S, Chung JH, Hammerberg C, Fisher GJ, Voorhees JJ. Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-kappaB and activator protein-1 in inflammatory acne lesions in vivo. Am J Pathol. 2005;166(6):1691-9. [Crossref] [PubMed] [PMC]
- Hauk L. Acne vulgaris: treatment guidelines from the AAD. Am Fam Physician. 2017;95(11):740-1. [PubMed]
- Kelhälä HL, Fyhrquist N, Palatsi R, Lehtimäki S, Väyrynen JP, Kubin ME, et al. Isotretinoin treatment reduces acne lesions but not directly lesional acne inflammation. Exp Dermatol. 2016;25(6):477-8. [Crossref] [PubMed]
- Tanacan E, Dincer D, Erdogan FG, Gurler A. A cutoff value for the Systemic Immune-Inflammation Index in determining activity of Behçet disease. Clin Exp Dermatol. 2021;46(2):286-91. [Crossref] [PubMed]
- Wang TC, An TZ, Li JX, Pang PF. Systemic inflammation response index is a prognostic risk factor in patients with hepatocellular carcinoma undergoing TACE. Risk Manag Healthc Policy. 2021;14:2589-600. [Crossref] [PubMed] [PMC]
- Chao B, Ju X, Zhang L, Xu X, Zhao Y. A novel prognostic marker Systemic Inflammation Response Index (SIRI) for operable cervical cancer patients. Front Oncol. 2020;10:766. [Crossref] [PubMed] [PMC]
- Zinellu A, Collu C, Nasser M, Paliogiannis P, Mellino S, Zinellu E, et al. The Aggregate Index of Systemic Inflammation (AISI): a novel prognostic biomarker in idiopathic pulmonary fibrosis. J Clin Med. 2021;10(18):4134. [Crossref] [PubMed] [PMC]
- Imtiaz F, Shafique K, Mirza SS, Ayoob Z, Vart P, Rao S. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int Arch Med. 2012;5(1):2. [Crossref] [PubMed] [PMC]
- Sen BB, Rifaioglu EN, Ekiz O, Inan MU, Sen T, Sen N. Neutrophil to lymphocyte ratio as a measure of systemic inflammation in psoriasis. Cutan Ocul Toxicol. 2014;33(3):223-7. [Crossref] [PubMed]
- Ozturk C, Balta S, Balta I, Demirkol S, Celik T, Turker T, et al. Neutrophil-lymphocyte ratio and carotid-intima media thickness in patients with Behçet disease without cardiovascular involvement. Angiology. 2015;66(3):291-6. [Crossref] [PubMed]
- Wang X, Meng H, Xu L, Chen Z, Shi D, Lv D. Mean platelet volume as an inflammatory marker in patients with severe periodontitis. Platelets. 2015;26(1):67-71. [Crossref] [PubMed]
- Djordjevic D, Rondovic G, Surbatovic M, Stanojevic I, Udovicic I, Andjelic T, et al. Neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume-to-platelet count ratio as biomarkers in critically ill and injured patients: which ratio to choose to predict outcome and nature of bacteremia? Mediators Inflamm. 2018;2018:3758068. [Crossref] [PubMed] [PMC]
- Yılmaz M, Kayançiçek H. A new inflammatory marker: elevated monocyte to HDL cholesterol ratio associated with smoking. J Clin Med. 2018;7(4):76. [Crossref] [PubMed] [PMC]
- Kanbay M, Solak Y, Unal HU, Kurt YG, Gok M, Cetinkaya H, et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol. 2014;46(8):1619-25. [Crossref] [PubMed]
- Işık M, Şahin H, Hüseyin E. New platelet indices as inflammatory parameters for patients with rheumatoid arthritis. Eur J Rheumatol. 2014;1(4):144-6. [Crossref] [PubMed] [PMC]
- Brzezinski P, Borowska K, Chiriac A, Smigielski J. Adverse effects of isotretinoin: a large, retrospective review. Dermatol Ther. 2017;30(4). [Crossref] [PubMed]
- Hansen TJ, Lucking S, Miller JJ, Kirby JS, Thiboutot DM, Zaenglein AL. Standardized laboratory monitoring with use of isotretinoin in acne. J Am Acad Dermatol. 2016;75(2):323-8. [Crossref] [PubMed]
- Özuğuz P, Kaçar S, Polat S, Ulu S, Karaca Ş. İsotretinoin tedavisinin nötrofil/lenfosit oranı ve diğer hemogram parametrelerine etkisinin değerlendirilmesi [Evaluation of the efficacy of isotretinoin treatment on neutrophil/lymphocyte ratio and the other hemogram parameters]. Mustafa Kemal Üniversitesi Tıp Dergisi. 2013;4(13):9-14. [Link]
- Seçkin HY, Baş Y, Takçı Z, Kalkan G. Effects of isotretinoin on the inflammatory markers and the platelet counts in patients with acne vulgaris. Cutan Ocul Toxicol. 2016;35(2):89-91. [PubMed]
- Ataseven A, Ugur Bilgin A. Effects of isotretinoin on the platelet counts and the mean platelet volume in patients with acne vulgaris. ScientificWorldJournal. 20142014:156464. [PubMed] [PMC]
- Önder S, Ozturk M. Can monocyte/HDL show inflammatory activity of isotretinoin treatment in acne patients? Cutan Ocul Toxicol. 2020;39(2):111-4. [Crossref] [PubMed]
- Cosansu NC, Yuksekal G, Turan U, Umitfer F, Yaldiz M, Sevimli Dikicier B. Investigation of systemic immune-inflammation index and systemic inflammation response index as an indicator of the anti-inflammatuary effect of isotretinoin in patients with acne vulgaris. Cutan Ocul Toxicol. 2022;41(2):174-8. [Crossref] [PubMed]
- Turan Ç, Metin N. A novel inflammatory marker in the follow-up of moderate-to-severe acne vulgaris administered isotretinoin: Systemic Immune-Inflammation Index (SII). Curr Health Sci J. 2022;48(1):63-7. [PubMed] [PMC]
- Tamer F, Yuksel ME, Avcı E. Is mean platelet volume an inflammatory marker in acne patients treated with isotretinoin? Acta Dermatovenerol Alp Pannonica Adriat. 2019;28(2):65-9. [Crossref] [PubMed]
- Kutlu Ö. Effect of isotretinoin treatment on the inflammatory markers in patients with acne vulgaris: can monocyte/HDL be a new indicator for inflammatory activity of isotretinoin treatment? Cutan Ocul Toxicol. 2020;39(1):67-70. [Crossref] [PubMed]
- Gencoglan G, Inanir I, Miskioglu M, Gunduz K. Evaluation of sequential effect of isotretinoin on the haematological parameters in patients with acne vulgaris. Cutan Ocul Toxicol. 2018;37(2):139-42. [Crossref] [PubMed]
- Karagöz Y, Tosun M. Effect of isotretinoin use on hematological parameters and biochemical values. Ann Clin Anal Med. 2022;13(4):355-9. [Link]
- Karadag AS, Ertugrul DT, Bilgili SG, Takci Z, Akin KO, Calka O. Immunoregulatory effects of isotretinoin in patients with acne. Br J Dermatol. 2012;167(2):433-5. [Crossref] [PubMed]
- Yavuz C. Neutrophil-lymphocyte ratio and C-reactive protein levels in acne vulgaris patients treated with systemic isotretinoin. Journal of Contemporary Med. 2021;11(6):774-7. [Crossref]
- Saklamaz A, Uyar B, Yalcin M, Cengiz H. Isotretinoin increased carotid intima-media thickness in acne patients. Hippokratia. 2016;20(1):14-8. [PubMed] [PMC]
- Hareedy MS, Tawfik KM. Systemic isotretinoin has an impact on hemoglobin, ferritin, urea, ceruloplasmin, albumin, uric acid levels, and neutrophil to lymphocyte ratio in acne patients. J Cosmet Dermatol. 2022;21(11):6191-8. [Crossref] [PubMed]
.: İşlem Listesi